Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
|Articles|May 1, 2006
- Pharmaceutical Executive-05-01-2006
- Volume 0
- Issue 0
Pharm Exec 50: The World's Top 50 Pharmaceutical Companies
Changing Landscapes: A Special Report on the World?s Top 50 Pharma Companies
Advertisement
Articles in this issue
over 20 years ago
More Than a Game of Keep Awayover 20 years ago
Teamsters v. Pfizerover 20 years ago
Leadership: It is Personalover 20 years ago
Legal: The Kickback Effectover 20 years ago
Washington Report: Opportunity Knocksover 20 years ago
From the Editor: Mixed Signalsover 20 years ago
Medicare Part D: D for Doomed?over 20 years ago
Thought Leader: Scientific Expressionover 20 years ago
Opinion: Brussels Sproutsover 20 years ago
Global Report: A Hope and a PayerAdvertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
How Preventative Medications May Impact the Lingering Impact of COVID-19
4
Rebuilding Clinical Data Workflows for the AI Era
5